Supply of clindamycin [as phosphate] 1% and benzoyl peroxide 5% (Duac Once Daily Gel) 6 g topical gel tubes by GlaxoSmithKline Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, serves to regulate the supply and advertising of therapeutic goods in Australia, ensuring their quality, safety, and efficacy. This Act was introduced to address the need for a comprehensive legal framework governing the oversight of therapeutic goods, which include medicines, medical devices, and blood and blood components. The Act aims to protect public health by ensuring that therapeutic goods are safe and of high quality. In the context of the Therapeutic Goods Act 1989, the policy objective is to maintain and enhance the safety and efficacy of therapeutic goods supplied in Australia, thereby protecting consumers from potential harm. The Therapeutic Goods Act 1989 allows the delegate of the Secretary of the Department of Health and Ageing to grant specific consents under certain conditions, as seen in the recent Gazette notice concerning the supply of clindamycin [as phosphate] 1% and benzoyl peroxide 5% (Duac Once Daily Gel) 6 g topical gel tubes by GlaxoSmithKline Australia Pty Ltd. This consent was granted to address a non-conformance with the Therapeutic Goods Order (TGO) 69, specifically concerning the labelling of the product. The consent is subject to conditions ensuring that the product in question meets the required standards and that any future batches will comply fully with the regulations. This demonstrates the Act’s role in providing regulatory flexibility while maintaining stringent quality and safety standards for therapeutic goods in Australia.

Scope and Application

The Therapeutic Goods Act 1989, specifically in relation to section 14 and 14A notice, pertains to the regulation and oversight of therapeutic goods supplied within Australia. This particular notice concerns the temporary consent given for the supply of a specific pharmaceutical product, clindamycin [as phosphate] 1% and benzoyl peroxide 5% (Duac Once Daily Gel) 6 g topical gel tubes, manufactured by GlaxoSmithKline Australia Pty Ltd. This consent applies to a particular batch of the product that has not yet been supplied and is subject to specific conditions to ensure compliance with regulatory standards. The consent is limited to batch 242P with an expiry date of March 2014, comprising approximately 2046 units, each containing 10 tubes. It is important to note that this consent does not extend to future batches, which must comply with the Therapeutic Goods Order (TGO) 69. This legislative framework is designed to maintain the quality, safety, and efficacy of therapeutic goods within the Commonwealth of Australia, and it applies to entities involved in the supply and distribution of such products.

Key Provisions

The Therapeutic Goods Act 1989 provides the legal framework for regulating therapeutic goods in Australia. Sections 14 and 14A of the Act, particularly in this context, allow the delegate of the Secretary of the Department of Health and Ageing to give consent for the supply of therapeutic goods that do not conform to certain requirements, provided that the non-conformity does not pose a significant risk to public health and safety. In this instance, section 14(1) and 14A(1) permit the delegate to consent to the supply of clindamycin [as phosphate] 1% and benzoyl peroxide 5% (Duac Once Daily Gel) 6 g topical gel tubes by GlaxoSmithKline Australia Pty Ltd, despite the product not meeting the labelling requirements as stipulated in paragraph 3(2)(l) of TGO 69. The obligations and requirements imposed by this consent include that the consent applies specifically to batch 242P of the product with an expiry date of March 2014, consisting of approximately 20,460 units, each containing 10 tubes. The tube labels must be identical to those previously supplied and contain details of the previous sponsor. The company must ensure that no other changes have been made to the product and must promptly redirect any customer correspondence addressed to the previous sponsor to themselves. Furthermore, all future batches of the product must comply with the requirements of TGO 69. The Act also sets out the consequences for breach of its provisions. While the specific section dealing with penalties is not detailed in this notice, breaches of the Therapeutic Goods Act 1989 can result in significant civil and criminal penalties. These may include fines for individuals and corporations, imprisonment for serious offences, and potential product recalls or market withdrawals. The maximum penalties can vary depending on the nature and severity of the breach, with higher penalties often associated with offences that pose a significant risk to public health and safety. It is important for entities governed by the Act to adhere strictly to its requirements to avoid these severe consequences.